Resveratrol inhibits doxorubicin‑induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes

  • Authors:
    • Mi‑Hua Liu
    • Jian Shan
    • Jian Li
    • Yuan Zhang
    • Xiao‑Long Lin
  • View Affiliations

  • Published online on: June 8, 2016     https://doi.org/10.3892/etm.2016.3437
  • Pages: 1113-1118
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Doxorubicin (DOX) is an efficient drug used in cancer therapy; however, it can induce severe cytotoxicity, which limits its clinical application. In the present study, the effects of resveratrol (RES) on sirtuin 1 (SIRT1) activation in mediating DOX‑induced cytotoxicity in H9c2 cardiac cells was investigated. H9c2 cells were exposed to 5 µM DOX for 24 h to establish a model of DOX cardiotoxicity. Apoptosis of H9c2 cardiomyocytes was assessed using the MTT assay and Hoechst nuclear staining. The results demonstrated that pretreating H9c2 cells with RES prior to the exposure of DOX resulted in increased cell viability and a decreased quantity of apoptotic cells. Western blot analysis demonstrated that DOX decreased the expression level of SIRT1. These effects were significantly alleviated by co‑treatment with RES. In addition, the results demonstrated that DOX administration amplified forkhead box O1 (FoxO1) and P53 expression levels in H9c2 cells. RES was also found to protect against DOX‑induced increases of FoxO1 and P53 expression levels in H9c2 cells. Furthermore, the protective effects of RES were arrested by the SIRT1 inhibitor nicotinamide. In conclusion, the results demonstrated that RES protected H9c2 cells against DOX‑induced injuries via SIRT1 activation.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu MH, Shan J, Li J, Zhang Y and Lin XL: Resveratrol inhibits doxorubicin‑induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Exp Ther Med 12: 1113-1118, 2016.
APA
Liu, M., Shan, J., Li, J., Zhang, Y., & Lin, X. (2016). Resveratrol inhibits doxorubicin‑induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Experimental and Therapeutic Medicine, 12, 1113-1118. https://doi.org/10.3892/etm.2016.3437
MLA
Liu, M., Shan, J., Li, J., Zhang, Y., Lin, X."Resveratrol inhibits doxorubicin‑induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes". Experimental and Therapeutic Medicine 12.2 (2016): 1113-1118.
Chicago
Liu, M., Shan, J., Li, J., Zhang, Y., Lin, X."Resveratrol inhibits doxorubicin‑induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes". Experimental and Therapeutic Medicine 12, no. 2 (2016): 1113-1118. https://doi.org/10.3892/etm.2016.3437